# Q32 Bio Inc. (QTTB) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_9440c5dff2e4ab71d8fd · retrieved 2026-08-12T06:57:23.755Z

## Overview
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, with its lead candidate bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, in Phase 2 development.

Q32 Bio Inc., a clinical-stage biotechnology company developing therapies for alopecia areata and other autoimmune diseases, completed a public offering in July 2026, raising gross proceeds of approximately $200.0 million through the sale of common stock and pre-funded warrants. The company stated that its cash and cash equivalents as of June 30, 2026 ($106.3 million), combined with proceeds from the July 2026 public offering, are expected to provide financial runway through Phase 3 topline results from its planned registration-directed program evaluating bempikibart in patients with severe or very severe alopecia areata.

## Terms
- Deal value: $200.0M · Consideration: mixed

## Key dates
- Announced 2026-08-05

## Timeline
- 2026-08-05 · 8-K (0001193125-26-333813): 8-K - Q32 Bio Inc. — *Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, with its lead candidate bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, in Phase 2 development.* Q32 Bio Inc., a clinical-stage biotechnology company developing therapies for alopecia areata and other autoimmune diseases, completed a public offering in July 2026, raising gross proceeds of approximately $200.0 million through the sale of common stock and pre-funded warrants. The company stated that its cash and cash equivalents as of June 30, 2026 ($106.3 million), combined with proceeds from the July 2026 public offering, are expected to provide financial runway through Phase 3 topline results from its planned registration-directed program evaluating bempikibart in patients with severe or very severe alopecia areata.
  https://www.sec.gov/Archives/edgar/data/1661998/0001193125-26-333813.txt

## Citations
- 0001193125-26-333813 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526333813